How is cimepilimab used? What are the indications?

Cemiplimab is a humanized anti-PD-1 monoclonal antibody mainly used to treat advanced or refractory malignant tumors. As an immune checkpoint inhibitor, it restores the ability of T cells to attack tumor cells by blocking the binding of programmed death receptor-1 (PD-1) and its ligands (PD-L1/PD-L2), thereby enhancing the anti-tumor immune response. The drug is administered by intravenous infusion, with the recommended dose usually being 350 mg, once every 3 weeks, with an infusion time of no less than 30 minutes, until disease progression or intolerable toxicity occurs.

Cimepilimab was first approved for the treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), and is suitable for patients who cannot undergo surgical resection or radiotherapy. Studies have shown that this drug can significantly improve the response rate and survival time of CSCC patients, making it an important treatment option in this field. In addition, cimepilimab is also approved for the treatment of patients with non-small cell lung cancer (NSCLC) with high PD-L1 expression, especially individuals who cannot receive platinum-based chemotherapy. In these patients, monotherapy provides durable antitumor activity and reduces chemotherapy-related toxicities.

In addition to CSCC and NSCLC, cimepilimab is also used to treat certain relapsed or refractory Barrett's lymphoma (R/R BCC) in patients who have failed or are intolerant to other systemic treatments. In recent years, the application of this drug in other tumor types (such as cervical cancer and melanoma) has been continuously researched and expanded, and some countries have included it in the treatment guidelines for corresponding indications. Due to its immunotherapeutic properties, cimepilimab can be used in combination with other therapies, such as chemotherapy, radiation therapy, or targeted therapy, to further enhance the effectiveness of the treatment.
In clinical application, cimepilimab may cause immune-related adverse reactions, such as pneumonia, hepatitis, thyroid dysfunction, skin toxicity, and colitis. Therefore, patients need to regularly monitor immune-related indicators during treatment and suspend or terminate treatment when serious adverse reactions occur. Overall, cimepilimab, as a PD-1 inhibitor, has shown good efficacy in a variety of solid tumors and provides a new treatment option for patients with advanced tumors.
Reference: https://www.libtayohcp.com/